Exploratory secondary analysis of a phase 3 trial in FLT3-ITD-positive AML (509 of 539 analysed): adding quizartinib to chemotherapy showed no substantial difference from placebo in global health status/quality of life (difference -2.0) or other patient-reported outcomes.
Secondary analysisn = 509
Olíva et al. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial